How to spell pain relief in the wake of COX-2 problems
Taking drugs of any kind is never without risks, but setbacks surrounding the vigorously marketed COX-2 inhibitors have really brought this home.
It's been tough going for pain relievers since the pharmaceutical company Merck pulled its COX-2 inhibitor rofecoxib (Vioxx) from the market in fall 2004, valdecoxib (Bextra) was pulled in March 2005, and the one remaining COX-inhibitor, celecoxib (Celebrex), was also found to have cardiovascular risks.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise